8 recruiting, 2 active not recruiting, 2 not yet recruiting, 1 completed. 9 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 5, Active not recruiting 2, Not yet recruiting 1, Unknown 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Marginal Zone Lymphoma(MZL): new trials by email Literature Review of Marginal Zone Lymphoma(MZL) trials Research Report on Marginal Zone Lymphoma(MZL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma Rituximab, Observation - Marginal Zone Lymphoma(MZL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 144 | 2026-07-01 | 2026-06-17 |
| Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma Zanubrutinib, Rituximab, and Lenalidomide as first-line treatment for Marginal Zone Lymphoma, Zanubrutinib, Rituximab, and Lenalidomide as the primary treatment for Marginal Zone Lymphoma - Marginal Zone Lymphoma(MZL) | Not applicable | Not yet recruiting | Zhengzhou University | 50 | 2026-01-01 | 2025-12-23 |
| Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma Orelabrutinib - Marginal Zone Lymphoma(MZL) | Phase 4 | Recruiting | Beijing Tongren Hospital | 88 | 2025-11-25 | 2026-01-21 |
| Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL Orelabrutinib, Zuberitamab, Cyclophosphamide - Marginal Zone Lymphoma(MZL) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 65 | 2025-10-01 | 2026-04-02 |
| Watch and Wait or Worry and Wait in Indolent Lymphoma Patient-Reported Outcomes Survey - Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma(MZL) | Enrolling by invitation | Seoul National University Hospital | 250 | 2025-10-01 | 2025-11-21 | |
| Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma Orelabrutinib (ICP-022), radiotherapy, Rituximab (R) - Marginal Zone Lymphoma of Ocular Adnexal, Marginal Zone Lymphoma(MZL) | Phase 2 | Active not recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 39 | 2025-09-19 | 2025-11-25 |
| Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL Orelabrutinib, Zebetuzumab, Lenalidomide - Marginal Zone Lymphoma(MZL) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 169 | 2025-08-14 | 2025-10-06 |
| A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies Lonitoclax (ZE50-0134) - CLL / SLL, CLL (Chronic Lymphocytic Leukemia) | Phase 1 | Recruiting | Lomond Therapeutics Holdings, Inc. | 84 | 2025-04-08 | 2026-07-31 |
| Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL Orelabrutinib, Rituximab, Lenalidomide - Marginal Zone Lymphoma(MZL) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 50 | 2025-04-01 | 2026-03-04 |
| Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma orelabrutinib combined with rituximab regimen - Marginal Zone Lymphoma(MZL) | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 51 | 2025-03-11 | 2025-06-15 |
| MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL Obinutuzumab and Orelabrutinib, Obinutuzumab, Orelabrutinib and Lenalidomide, Orelabrutinib - Marginal Zone Lymphoma(MZL) | Phase 2 | Recruiting | Ruijin Hospital | 145 | 2025-01-23 | 2026-03-24 |
| Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP) Marginal Zone Lymphoma(MZL) | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 59 | 2024-12-09 | 2025-02-12 | |
| Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial Orelabrutinib, rituximab, Cyclophosphamide - Marginal Zone Lymphoma(MZL) | Phase 2 | Recruiting | Fei Li | 90 | 2024-12-01 | 2025-06-17 |
| Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Completed | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 102 | 2022-02-21 | 2025-01-20 | |
| Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma SHC014748M - Follicular Lymphoma(FL), Marginal Zone Lymphoma(MZL) | Phase 2 | Unknown | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 122 | 2020-05-09 | 2021-01-28 |
Lymphoma, B-Cell, Marginal Zone (15) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Follicular (3) · Waldenstrom Macroglobulinemia (2) · Leukemia, B-Cell (1) · Leukemia, Hairy Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell (1) · Mycosis Fungoides (1) · Recurrence (1) · Tumor Lysis Syndrome (1)
Hemic and Lymphatic Diseases (15) · Immune System Diseases (15) · Immunoproliferative Disorders (15) · Lymphatic Diseases (15) · Lymphoma (15) · Lymphoma, B-Cell (15) · Lymphoma, Non-Hodgkin (15) · Lymphoproliferative Disorders (15) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Chronic Disease (3) · Disease Attributes (3) · Hematologic Diseases (3) · Leukemia (3) · Leukemia, Lymphoid (3)
Rituximab (7) · orelabrutinib (7) · Lenalidomide (4) · Cyclophosphamide (2) · Vincristine (2) · obinutuzumab (2) · Bendamustine Hydrochloride (1) · Calcium Dobesilate (1) · Observation (1) · Prednisone (1) · Radiotherapy (1) · zanubrutinib (1)
IRCCS Azienda Ospedaliero-Universitaria di Bologna (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · The First Affiliated Hospital with Nanjing Medical University (2) · Beijing Tongren Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fei Li (1) · Lomond Therapeutics Holdings, Inc. (1) · Nanjing Sanhome Pharmaceutical, Co., Ltd. (1) · Ruijin Hospital (1) · Seoul National University Hospital (1) · Sun Yat-sen University (1) · Zhengzhou University (1)
China (10) · Italy (2) · South Korea (1) · United States (1)
Fei Li, professor (1) · Ja Min Byun, MD, PhD (1) · Jianyong Li, MD (1) · Liang Wang, MD (1) · Lucia Catani, PhD (1) · Pier Luigi Zinzani, MD (1) · Xinxin Cao, doctor (1)